The report provides market dynamics and estimation, trends, and forecast related to the global implantable drug delivery devices market. Implantable drug delivery devices are used to administer drugs and fluids to the body, without repeated insertion of needles. Drug delivery is the process of administering a pharmaceutical substance to achieve therapeutic effects in humans. Over the past decade, there has been increase in convergence between drug therapies and implantable devices such as drug eluting stents, osmotic pumps, and implantable rods, which deliver drugs to specific targeted areas

The companies in the global digital surgery technologies market are the manufacturers and providers of digital surgery technology products, such as manufacturers of simulation systems, leading medical device OEMs, emerging tech-startups developing AI-algorithm tools, and software platforms related to surgical data science. Thus, the market includes both the established players such as Medtronic, Brainlab, and tech giants such as Google, Facebook, and IBM, as well as emerging digital surgery technology product manufacturers. Big companies are taking great interest in AI. IBM, Microsoft, Google, LinkedIn, Facebook, Intel, and Fujitsu were some of the machine learning patent producers in 2017. More than 300 healthcare patents were filed between 2013 and 2017: 186 by Alphabet, 73 by Microsoft, and 54 by Apple.

The report provides market dynamics and trends related to the global HIV drugs market. In addition, it presents the estimations and forecast of the market. The study estimates the revenue generated from the sales of HIV drugs products; however, it excludes the HIV drugs service revenue. The valuations comprise revenue generated from HIV drugs products such as into multi-class combination drugs, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), entry inhibitors - CCR5 co-receptor antagonist, and HIV integrase strand transfer inhibitors. Furthermore, the report excludes revenue generated from post-sale services of HIV drugs products.

Breast cancer liquid biopsy is a cancer diagnostics test executed to understand molecular aspects of breast cancer across healthcare and research settings, such as hospitals, physicians, and pathological and research laboratories. It is a non-invasive blood test that provides researchers, physicians, and surgeons with information about cancer profile of a patient and appropriate therapy to improve survival rate of such patients. The report provides market dynamics and trends related to the global breast cancer liquid biopsy market. The study estimates revenue generated from sales of breast cancer liquid biopsy products and services. The valuations comprise revenue generated from reagents, instruments, and services.

Currently, the COVID-19 diagnostic testing industry is witnessing exponential growth due to the growing number of cases worldwide coupled with the massive issuance of emergency use authorizations (EUAs) from the regulatory bodies to the manufacturers. Currently, reverse transcriptase-polymerase chain reaction (RT-PCR) is expected to remain the gold standard for COVID-19 diagnostic testing. However, the development of novel diagnostic technologies by the manufacturers such as isothermal amplification, clustered regularly interspaced short palindromic repeats (CRISPR), and droplet digital polymerase chain reaction (ddPCR) are expected to provide new avenues for improved COVID-19 diagnosis.

Immunotherapy has emerged as an innovative treatment option over decades, as it harnesses the patient’s immune system to attack cancer. In 1891, William B. Coley, MD, first attempted to harness the immune system for treating cancer. The scientific community has been pursuing research for the development of CAR T-cell therapy over a century. The engineered CAR T-cell receptors were first created and developed in 1987 by Dr. Zelig Eshhar, an Israeli immunologist from the Weizmann Institute of Science, Israel. On August 30, 2017, Kymriah (Tisagenlecleucel), a synthetic bio immune product of anti-CD19 chimeric antigen receptor (CAR) T-cells, was approved by the U.S. FDA for the treatment of cancers such as relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). Novarts AG is the first company to get approval for the first CAR T-cell immunotherapy. Currently, CAR T-cell therapy is developed by more than 100 companies across the globe.

The skin forms the outer covering of the body, consisting of two specialized layers, i.e., the dermis and the epidermis. It is the largest organ of the integumentary system and performs a wide range of functions such as protecting from microbes and other foreign elements, regulating body temperature, and permitting the sensations of touch, heat, and cold. Skin substitutes are alternatives to replace the functions of the skin that can provide temporary or permanent coverage to open skin wounds. Also called dermal substitutes, skin alternatives encompass an array of biological products, including biological skin substitutes (allograft and xenograft), amniotic and placenta tissues, synthetic skin, and bioengineered skin substitutes. They are a heterogeneous group of biologic, synthetic, or biosynthetic materials that mainly aim to replicate the properties of the normal skin.

A biobank is a facility that is involved in the collection, preservation, processing, storage, and supply of biological biospecimens and associated data, which follows standardized operating procedures and provides biospecimen for scientific and clinical use. For the purpose of analysis, the global biobank market is segmented into specimen type, type of biobank, ownership, application, and region. The market study provides the dynamics and trends of the global biobanking market. It offers market estimations and forecasts for the biobanking services such as collection, preservation, processing, storage, and distribution. However, it excludes the revenue generated from the equipment, consumables, and software used in biobanks. Furthermore, excluded revenue generated from environmental repositories services.

The global drug delivery systems market has witnessed major transformation in the recent years from conventional syringes to pre-filled syringes including auto-injectors and pen injectors. As technology is advancing, efforts are being made to invent novel drug delivery methods, which are convenient, accurate, safe, and affordable.

Disinfectant and antimicrobial chemicals are used for inhibiting the growth of microorganisms. These specialty chemicals are used to keep house, offices, schools, industrial equipment, processing facilities, and other public places clean & hygienic. Antimicrobial chemicals include antiseptics, antibiotics, antifungals, antiprotozoals, and antivirals, whereas disinfectants include alcohols, aldehydes, and phenolic compounds. For the purpose of analysis, the report segments the global antimicrobial & disinfectant chemicals market based on function, product type, end use, and region. The report provides information about the various functions of antimicrobial & disinfectant chemicals, including disinfectant & sanitizer and antimicrobial additives. Phenolic, iodophors, nitrogen compounds, organometallics, organosulfur, aldehydes, and other chemicals are the different product types covered in the study. The major end users of antimicrobial & disinfectant chemicals are paint & coatings, food & beverage processing, medical & health care, plastics, textiles, and other industries. The report further outlines the details about the revenue generated by antimicrobial & disinfectant chemicals across North America, Europe, Asia-Pacific, and LAMEA.